Novogen Limited (KZIA) – What Are Researchers Saying About This Stock?

Shares of Novogen Limited (NASDAQ:KZIA) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $28.80.

KZIA has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Canaccord Genuity Group began coverage on Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Novogen in a report on Thursday, September 10th.

Novogen Price Performance

KZIA opened at $8.04 on Wednesday. Novogen has a one year low of $4.86 and a one year high of $17.40. The stock’s fifty day moving average is $11.64 and its 200-day moving average is $11.99.

About Novogen

Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.